Browse by author
Lookup NU author(s): Dr Mario Abinun
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2023 American Academy of Allergy, Asthma & ImmunologyBackground: Elevated TCRαβ+CD4−CD8− double-negative T cells (DNT) and serum biomarkers help identify FAS mutant patients with autoimmune lymphoproliferative syndrome (ALPS). However, in some patients with clinical features and biomarkers consistent with ALPS, germline or somatic FAS mutations cannot be identified on standard exon sequencing (ALPS-undetermined: ALPS-U). Objective: We sought to explore whether complex genetic alterations in the FAS gene escaping standard sequencing or mutations in other FAS pathway–related genes could explain these cases. Methods: Genetic analysis included whole FAS gene sequencing, copy number variation analysis, and sequencing of FAS cDNA and other FAS pathway–related genes. It was guided by FAS expression analysis on CD57+DNT, which can predict somatic loss of heterozygosity (sLOH). Results: Nine of 16 patients with ALPS-U lacked FAS expression on CD57+DNT predicting heterozygous “loss-of-expression” FAS mutations plus acquired somatic second hits in the FAS gene, enriched in DNT. Indeed, 7 of 9 analyzed patients carried deep intronic mutations or large deletions in the FAS gene combined with sLOH detectable in DNT; 1 patient showed a FAS exon duplication. Three patients had reduced FAS expression, and 2 of them harbored mutations in the FAS promoter, which reduced FAS expression in reporter assays. Three of the 4 ALPS-U patients with normal FAS expression carried heterozygous FADD mutations with sLOH. Conclusion: A combination of serum biomarkers and DNT phenotyping is an accurate means to identify patients with ALPS who are missed by routine exome sequencing.
Author(s): Rensing-Ehl A, Lorenz MR, Fuhrer M, Willenbacher W, Willenbacher E, Sopper S, Abinun M, Maccari ME, Konig C, Haegele P, Fuchs S, Castro C, Kury P, Pelle O, Klemann C, Heeg M, Thalhammer J, Wegehaupt O, Fischer M, Goldacker S, Schulte B, Biskup S, Chatelain P, Schuster V, Warnatz K, Grimbacher B, Meinhardt A, Holzinger D, Oommen PT, Hinze T, Hebart H, Seeger K, Lehmberg K, Leahy TR, Claviez A, Vieth S, Schilling FH, Fuchs I, Gross M, Rieux-Laucat F, Magerus A, Speckmann C, Schwarz K, Ehl S
Publication type: Article
Publication status: Published
Journal: Journal of Allergy and Clinical Immunology
Year: 2024
Volume: 153
Issue: 1
Pages: 297-308.e12
Print publication date: 01/01/2024
Online publication date: 16/11/2023
Acceptance date: 09/11/2023
ISSN (print): 0091-6749
ISSN (electronic): 1097-6825
Publisher: Elsevier Inc.
URL: https://doi.org/10.1016/j.jaci.2023.11.006
DOI: 10.1016/j.jaci.2023.11.006
PubMed id: 37979702
Altmetrics provided by Altmetric
